Search research articles
Contact Us
Filters
Showing results (31-40 of 260) with videos related to
Page
of 26
Sort By:
Cancer Research
|
December 1, 2018
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A Stewart, Patrick G Pilié, Timothy A Yap
British Journal of Cancer
|
March 30, 2016
PARP inhibitors: the race is on
Jessica S Brown, Stan B Kaye, Timothy A Yap
JCO Precision Oncology
|
July 12, 2021
Global Implementation of Precision Oncology
Clinton Yam, Brigette B Y Ma, Timothy A Yap
Translational Oncogenomics
|
November 27, 2015
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
Juanita Lopez, Sam Harris, Desam Roda, et al.
Current Opinion in Oncology
|
May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers
Craig P Carden, Timothy A Yap, Stan B Kaye
The EPMA Journal
|
June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
Timothy A Yap, Charles Swanton, Johann S de Bono
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2013
Development of therapeutic combinations targeting major cancer signaling pathways
Timothy A Yap, Aurelius Omlin, Johann S de Bono
Cancer
|
May 5, 2025
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic
Elise Nassif Haddad, Milind M Javle, Timothy A Yap
Journal of Thoracic Disease
|
November 22, 2016
Emerging strategies for the treatment of advanced small cell lung cancer
Joline S J Lim, Dearbhaile Collins, Timothy A Yap
Nature Reviews. Cancer
|
February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A Yap, Craig P Carden, Stan B Kaye
Page
of 26
Search research articles
Search
Showing results (31-40 of 260) with videos related to
Sort By:
Page
of 26
Cancer Research
|
December 1, 2018
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A Stewart, Patrick G Pilié, Timothy A Yap
British Journal of Cancer
|
March 30, 2016
PARP inhibitors: the race is on
Jessica S Brown, Stan B Kaye, Timothy A Yap
JCO Precision Oncology
|
July 12, 2021
Global Implementation of Precision Oncology
Clinton Yam, Brigette B Y Ma, Timothy A Yap
Translational Oncogenomics
|
November 27, 2015
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
Juanita Lopez, Sam Harris, Desam Roda, et al.
Current Opinion in Oncology
|
May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers
Craig P Carden, Timothy A Yap, Stan B Kaye
The EPMA Journal
|
June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
Timothy A Yap, Charles Swanton, Johann S de Bono
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2013
Development of therapeutic combinations targeting major cancer signaling pathways
Timothy A Yap, Aurelius Omlin, Johann S de Bono
Cancer
|
May 5, 2025
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic
Elise Nassif Haddad, Milind M Javle, Timothy A Yap
Journal of Thoracic Disease
|
November 22, 2016
Emerging strategies for the treatment of advanced small cell lung cancer
Joline S J Lim, Dearbhaile Collins, Timothy A Yap
Nature Reviews. Cancer
|
February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A Yap, Craig P Carden, Stan B Kaye
Page
of 26